Cargando…
4-Year Cost Trajectories in Real-World Patients Matched to the Metabolic Profiles of Trial Subjects Before/After Treatment with Phentermine-Topiramate
OBJECTIVE: Our objective was to estimate 4-year healthcare costs associated with the metabolic profile of patients before and after 1 year of treatment with phentermine (15 mg) and topiramate extended-release (92 mg) [phentermine-topiramate ER]. DESIGN AND METHODS: Using a medical records database,...
Autores principales: | Li, James, Reaven, Nancy L., Funk, Susan E., McGaughey, Karen, Neovius, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883189/ https://www.ncbi.nlm.nih.gov/pubmed/27747764 http://dx.doi.org/10.1007/s40801-015-0021-x |
Ejemplares similares
-
Phentermine and topiramate for the management of obesity: a review
por: Cosentino, Gina, et al.
Publicado: (2011) -
Phentermine-topiramate: First combination drug for obesity
por: Singh, Jagjit, et al.
Publicado: (2015) -
Cardiovascular Safety During and After Use of Phentermine and Topiramate
por: Ritchey, Mary E, et al.
Publicado: (2018) -
Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
por: Garvey, W. Timothy, et al.
Publicado: (2014) -
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
por: Shin, Jin Hee, et al.
Publicado: (2013)